Article Sidebar

Submitted
March 31, 2021
Accepted
December 18, 2023
Published
December 30, 2023
Download
PDF (Bahasa Indonesia)
Statistic
Read Counter : 608 Download : 625

Downloads

Download data is not yet available.

Main Article Content

Abstract

Background: Preeclampsia in pregnant women can occur with elevated blood pressure >140/90 mmHg. Nifedipine and methyldopa can be used as antihypertensive therapy in pre-eclampsia patients. These two drugs have differences in their mechanisms of action to decrease blood pressure.
Objective: To evaluate the effects of nifedipine and methyldopa in hospitalized pregnant female patients at RSUD Dr. H. Moch. Ansari Saleh from January to December 2018.
Method: This research method was descriptive-observational, obtaining data retrospectively. This research included 30 hypertensive pregnant women who were divided into the nifedipine group or the methyldopa group. The blood pressure measurements of the patients were documented before and after therapy. The data was evaluated with an independent sample t-test.
Result: The outcomes of this research indicated that nifedipine reduced the systolic blood pressure from the average of 159.33 to 127.66 mmHg and in the methyldopa group from the average of 162.67 to 137.33 mmHg (p < 0.05). The mean arterial pressure (MAP) after using nifedipine was 99.44 ± 10.15 mmHg, and after using methyldopa, it was 106.22 ± 7.65 mmHg (p <0.05).
Conclusion: Nifedipine was more effective than methyldopa in lowering blood pressure in pre-eclampsia subjects.
Keywords: Nifedipine, methyldopa, hypertension, blood pressure


Intisari
Latar belakang: Ciri-ciri hipertensi pada ibu hamil ditandai dengan peningkatan tensi darah diatas 140/90 mmHg yang dapat menyebabkan terjadinya preeklampsia. Nifedipin dan metildopa digunakan sebagai terapi antihipertensi khususnya pada pasien preeklampsia. Kedua obat tersebut memiliki perbedaan pada mekanisme kerja untuk mengurangi tekanan pada pembuluh arteri.
Tujuan: Menganalisa efek pemakaian obat nifedipin dan metildopa pada subyek wanita hamil dan dirawat inap di RSUD Dr. H. Moch. Ansari Saleh di tahun 2018.
Metode: Jenis penelitian ini adalah observasional deskriptif dengan memperoleh data secara retrospektif. Jumlah subyek sebanyak 30 pasien ibu hamil dengan kondisi hipertensi dibagi menjadi kelompok nifedipin atau kelompok metildopa. Data tekanan darah diambil sebelum dan sesudah pengobatan yang diperoleh dari rekam medis pasien yang kemudian diuji dengan independent sample t-test.
Hasil: Nifedipin dapat mengurangi tekanan darah sistolik dari rerata 159,33 mmHg ke 127,66 mmHg dan pada grup metildopa dari rerata 162,67 mmHg ke 137,33 mmHg (p <0,05). Hasil rerata tekanan arteri (MAP) subyek setelah menggunakan nifedipin yaitu 99,44 ± 10,15 mmHg dan pada metildopa yaitu 106,22 ± 7,65 mmHg (p <0,05).
Kesimpulan: Nifedipin lebih efektif dibandingkan dengan metildopa dalam menurunkan tensi darah pada wanita hamil dengan preeklampsia.
Kata kunci: Nifedipin, metildopa, hipertensi, tekanan darah

Keywords

nifedipine methyldopa hypertension blood pressure

Article Details

License

Copyright (c) 2023 Jurnal Ilmiah Farmasi

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish in the Jurnal Ilmiah Farmasi agree to the following terms:

  1. Authors retain copyright and grant Jurnal Ilmiah Farmasi right of first publication with the work simultaneously licensed under a Creative Commons Attribution Licence that allows others to adapt (remix, transform, and build) upon the work non-commercially with an acknowledgement of the work's authorship and initial publication in Jurnal Ilmiah Farmasi.
  2. Authors are permitted to share (copy and redistribute) the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in Jurnal Ilmiah Farmasi.
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Brown M. A., Magee L. A., Kenny L. C., Karumanchi S. A., McCarthy F. P., Saito S., Hall D. R., Warren C. E., Adoyi G., & Ishaku S. (2018). Hypertensive Disorders of Pregnancy. Hypertension, 72(1), 24–43. https://doi.org/10.1161/HYPERTENSIONAHA.117.10803
  2. Butalia S., Audibert F., Côté A.-M., Firoz T., Logan A. G., Magee L. A., Mundle W., Rey E., Rabi D. M., Daskalopoulou S. S., & Nerenberg K. A. (2018). Hypertension Canada’s 2018 Guidelines for the Management of Hypertension in Pregnancy. Canadian Journal of Cardiology, 34(5), 526–531. https://doi.org/10.1016/j.cjca.2018.02.021
  3. Dayani T. R., & Widyantari K. Y. (2023). Faktor-Faktor Yang Berhubungan Dengan Kejadian Hipertensi Pada Ibu Hamil. Journal of Language and Health, 9(1), 1–10. https://jle.hse.ru/issue/view/1099/Volume 9 Issue 1
  4. Dublin S., Idu A., Avalos L. A., Cheetham T. C., Easterling T. R., Chen L., Holt V. L., Nance N., Bider-Canfield Z., Neugebauer R. S., Reynolds K., Badon S. E., & Shortreed S. M. (2022). Maternal and Neonatal Outcomes of Antihypertensive Treatment In Pregnancy: A Retrospective Cohort Study. PLoS ONE, 17, 1–14. https://doi.org/10.1371/journal.pone.0268284
  5. Easterling T., Mundle S., Bracken H., Parvekar S., Mool S., Magee L. A., von Dadelszen P., Shochet T., & Winikoff B. (2019). Oral Antihypertensive Regimens (Nifedipine Retard, Labetalol, And Methyldopa) For Management of Severe Hypertension In Pregnancy: An Open-Label, Randomised Controlled Trial. The Lancet, 394(10203), 1–11. https://doi.org/10.1016/S0140-6736(19)31282-6
  6. Garovic V. D., Dechend R., Easterling T., Karumanchi S. A., Baird S. M., Magee L. A., Rana S., & Vermunt J. V. (2022). Hypertension in Pregnancy : Diagnosis, Blood Pressure Goals, and Pharmacotherapy : In Hypertension (Vol. 79, Issue 2). https://doi.org/10.1161/HYP.0000000000000208.Hypertension
  7. Kundarto W., & Faizah R. N. (2021). Evaluasi Terapi Antihipertensi Pada Pasien Preeklampsia Berat di Instalasi Rawat Inap RSUD Dr. Moewardi Periode Januari - Juni Tahun 2017. JPSCR: Journal of Pharmaceutical Science and Clinical Research, 6(2), 228–237. https://doi.org/10.20961/jpscr.v6i2.39487
  8. Ngene N. C., & Moodley J. (2020). Pre-eclampsia With Severe Features: Management of Antihypertensive Therapy In The Postpartum Period. Pan African Medical Journal, 36(216), 1–15. https://doi.org/10.11604/pamj.2020.36.216.19895
  9. Okamoto T., Watanabe K., Banno T., Saitou T., Sugiura K., Iwasaki A., Matsushita H., & Wakatsuki A. (2022). Amount of Proteinuria As Associated With Severity Classification of Pregnant Women With Preeclampsia. Pregnancy Hypertension, 29, 30–35. https://doi.org/10.1016/j.preghy.2022.05.009
  10. Purwanti S. (2022). Risiko Preeklampsia pada Ibu Bersalin di RSUD dr. Moch Ansari Saleh. JIKES: Jurnal Ilmu Kesehatan , 1(1), 47–52. http://qjurnal.my.id/index.php/jik/article/view/89
  11. Togarikar S. M. (2017). Efficacy of Methyldopa Versus Nifedipine In Mild and Severe Pregnancy Induced Hypertension. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 6(10), 4544–4548. https://doi.org/10.18203/2320-1770.ijrcog20174439
  12. Vanwye W. R., Weatherholt A. M., Winchester L. J., Owens J. G., & Spears M. (2023). Cardiovascular Responses During Light-intensity Aerobic Exercise with Varying Levels of Limb Occlusion Pressures. International Journal of Exercise Science, 16(2), 676–687. https://digitalcommons.wku.edu/ijes/vol16/iss2/12
  13. Yana A. U., Brata C., & Irawati S. (2023). Studi Penggunaan Antihipertensi pada Pasien Preeklampsia Rawat Jalan di Poliklinik Rumah Sakit Ibu dan Anak Surabaya. Jurnal Kesehatan, 14(2), 319–326. https://doi.org/10.26630/jk.v14i2.3893